Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Therapeutic Development Award (TDA)

The summary for the Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Therapeutic Development Award (TDA) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense Fiscal Year 2004 Neurofibromatosis Research Program (NFRP) Therapeutic Development Award (TDA): The intent of the Therapeutic Development Award is to sponsor the development of therapeutics, as well as tools for their evaluation in preclinical model systems of NF1, NF2, and/or Schwannomatosis. The overall goal of this award mechanism is to allow investigators to develop the means to analyze preclinical efficacy of novel and existing agents and/or to generate the preclinical data necessary to conduct NF-relevant clinical trials after completion of the proposed research. The proposed studies are expected to be empirical in nature and product-driven, but may have a hypothesis-driven approach provided the focus is on therapeutics. It is anticipated that the agents, model systems, or data generated from these awards will lead to the advancement of therapeutics novel to NF1, NF2, and/or Schwannomatosis and to the development of a broad platform on which to test future therapies.